Therapy for Pediatric Relapsed/Refractory ALL
Acute Lymphoblastic Leukemia
Enrolment: 47 · Results not recorded
Loading the evidence…
Drug · DNA topoisomerase II alpha inhibitor; DNA inhibitor (INHIBITOR)
2 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.
Acute Lymphoblastic Leukemia
Enrolment: 47 · Results not recorded
Acute Lymphoblastic Leukemia
Enrolment: 3 · Results not recorded
Acute Myeloid Leukemia
Enrolment: 500 · Results not recorded
Lymphoma, Follicular
Enrolment: 14 · Results not recorded
Diffuse Large B-Cell Lymphoma
Enrolment: 50 · Results not recorded
Leukemia
Enrolment: 79 · Results not recorded
Lymphoma
Enrolment: 20 · Results not recorded
Breast Cancer
Enrolment not recorded · Results not recorded
Prostatic Neoplasms
Enrolment: 10 · Results not recorded
Acute Myeloid Leukemia
Enrolment: 12 · Results not recorded
1 studies reported at therapy level; 1 evidence entries itemised.
Model: Intratracheal lipopolysaccharide induced acute lung injury (2 mg/kg body weight for 24 h)
Both lentiviral knockdown of USP11 and intratracheal mitoxantrone attenuated lipopolysaccharide induced increases in bronchoalveolar lavage protein, IL-6 and KC, and reduced neutrophil influx into alveolar spaces, consistent with reduced LPA1 stability and diminished LPA1-CD14 signalling.
Extraction: extract · Supplied extraction confidence: 0.85. Machine-extracted fields require source verification.